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A b s t r a c t
Introduction: Survival after heart transplantation (HTX) is extended due to 
continuous improvement of  medical care, allowing enough time for coro-
nary artery vasculopathy to develop. Data on the clinical outcome of cardiac 
transplantation patients after percutaneous coronary intervention (PCI) are 
still not extensively explored. The aim of our study was to assess whether 
heart transplantation itself compromises the outcome in patients undergo-
ing percutaneous coronary intervention and to assess survival rates as well 
as major cardiovascular complications in heart transplant recipients who 
had undergone PCI.
Material and methods: Thirty-three heart transplant recipients who had un-
dergone PCI in the years 2005 to 2015 in a single center were matched by age, 
sex and main risk factors of arteriosclerosis with 33 controls without heart 
transplant history. Mean age of  patients was 54.6 ±11.4 years in the  HTX 
group and 58.8 ±10.8 years in controls. Median time from heart transplant 
to PCI was 13 years (4.4–22 years). Case and control groups did not differ in 
terms of standard risk factors of coronary artery disease, apart from chronic 
kidney disease, which was present in 70% of patients after heart transplan-
tation, and dyslipidemia, which was present in 91% of control subjects.
Results: Patients after HTX had worse survival compared to controls 
(p  =  0.04). When adjusted for comorbidities in the  Cox regression model, 
there was no significant difference in survival between cardiac transplant 
recipients and the control group (HR = 1.06; 95% CI: 0.10–11.24). Chronic 
renal disease was a significant predictor of all-cause mortality (HR = 29.9; 
95% CI: 2.3–393). Considering other endpoints, HTX patients had consider-
ably higher incidence of severe bleeding compared to the control group (27% 
vs. 3%, p < 0.05). 
Conclusions: There was no significant difference in myocardial infarction 
rate, revascularization or hospitalization rates.
Key words: heart transplantation, percutaneous coronary intervention, 
survival analysis.
Introduction
Graft vasculopathy (GV) is one of the most important reasons for graft 
failure [1]. It is also a main reason for stenosis formation in graft epicar-
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dial arteries, in contrast to non-transplant heart, 
where arteriosclerotic plaque is mainly responsi-
ble for myocardial ischemia [2]. The mechanisms 
of GV are increasingly understood. It is a combi-
nation of autoimmune response, cytomegalovirus 
(CMV) infection, ischemia-reperfusion and preser-
vation damage. All these processes lead to vas-
cular inflammation contributing to endothelial 
dysfunction that additionally affects donor-trans-
mitted arteriosclerosis. This leads to transplant 
atherosclerosis  [3]. From available studies, it is 
known that GV progresses and after 15 years 
since heart transplantation (HTX) significant GV 
is diagnosed among 40% of patients. This leads 
to higher mortality compared to GV free subjects. 
Percutaneous angioplasty improves this out-
come [4]. 
Guidelines suggest performing coronary an-
giography even as frequently as once a  year in 
patients after heart transplant [5, 6]. As HTX pa-
tients are mostly angina free, coronary stenosis is 
sometimes a random finding and often accompa-
nies the  graft rejection process. The  main path-
omechanism of  coronary stenosis in the  graft is 
an autoimmunologic inflammatory response and 
infection causing vascular inflammation leading 
to endothelial dysfunction [7–10]. 
Having little data in the literature on the long-
term follow-up in patients after HTX, to date we 
know that those patients benefit from percutane-
ous coronary intervention (PCI) in the case of GV. 
But we still do not know which factors influence 
outcomes. In the literature, there are limited avail-
able data showing predictors of higher mortality 
among those patients, but different comorbidi-
ties tend to progress after HTX [11]. Development 
of heart failure (ejection fraction (EF) < 40 or sys-
tolic blood pressure (SBP) < 90 mm Hg) were inde-
pendent survival predictors in HTX patients after 
PCI. Chronic kidney disease was among the pre-
dictors but it was insignificant. Dyslipidemia treat-
ment had a beneficial influence on those patients. 
Interventions on the  right coronary artery (RCA) 
did not seem to influence outcomes, whilst PCI on 
other vessels was a significant predictor of surviv-
al [4, 12]. It is interesting how HTX itself influences 
outcomes.
The aim of  our study was to assess whether 
heart transplantation itself compromises the out-
come in patients undergoing percutaneous coro-
nary intervention and to assess survival rates as 
well as major cardiovascular complications in heart 
transplant recipients who had undergone PCI.
Material and methods
We investigated 33 heart transplant recipients 
who underwent coronary angiography and PCI due 
to medical indications, in the Department of Inter-
ventional Cardiology (Jagiellonian University, John 
Paul II Hospital), Krakow, Poland. Those patients 
were compared with other 33 patients without 
heart transplant history. This control group was 
matched by age, sex and main risk factors of coro-
nary artery disease from a cohort of patients with 
stable coronary artery disease, after PCI but with-
out a history of heart transplant.
This patient selection process was done by 
the  head-to-head method. Matching between 
groups was based on age, arterial hypertension, 
diabetes (type 2, on oral or insulin therapy), obe-
sity (body mass index  (BMI) >  30 kg/m2), prior 
acute coronary syndrome and target vessel. 
The  head-to-head matching method was used, 
as propensity score matching involves regression 
analysis, which was planned for use in Cox mod-
els. Chronic kidney disease (stage 3 and 4) was 
more frequent in patients with HTX (vs. control; 
p < 0.001). We found a major difference between 
groups in comorbidities of patients at the same 
age and the same occurrence of main risk factors 
(hypertension, diabetes, obesity, prior acute cor-
onary syndrome  (ACS)). Thus, propensity score 
matching was difficult to achieve. All patients 
underwent planned angiography due to medical 
indications. 
We followed up patients in an  out-patient 
clinic. Endpoints were assessed in all the  pa-
tients during the follow-up. Data concerning ACS, 
stroke, and any cause of  hospitalization were 
recorded and classified according to the ICD-10. 
CV endpoint was defined as occurrence of ACS, 
stroke and death due to these conditions. Deaths 
not caused by these conditions were classified 
as non-CV death. Composite endpoint (MACCE) 
was identified as a combination of CV endpoint 
with non-CV mortality, providing all-cause mor-
tality. Bleeding was defined according to GUSTO 
bleeding criteria. 
The study was a part of a statutory grant ap-
proved by the Jagiellonian University Ethics Com-
mittee.
Statistical analysis
Continuous variables were presented as a mean 
value with standard deviation or as a percentage for 
categorical values. Unless stated otherwise, com-
parison of means was performed with the two-sid-
ed t-test for variables with normal distribution and 
with the non-parametric Mann-Whitney U test for 
distributions other than normal. The Kaplan-Meier 
estimator with log-rank test was used to assess 
survival of patients. Furthermore, multifactorial Cox 
regression analysis with adjustment for age, sex 
and comorbidities was applied to explore risk fac-
tors of death. In all analyses 0.05 was adopted as 
the  level of  significance. Statistical analyses were 
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es between the HTX and control group occurred 
in creatinine levels (204 ±32 vs. 105 ±12 mM; 
p  =  0.006), estimated glomerular filtration rate 
(eGFR) as well as in hemoglobin levels (12.6 ±0.4 
vs. 14.0 ±0.3 g/dl; p = 0.01). We also found that 
platelet counts were lower in the HTX group (187 
±8 vs. 241 ±11; 103/mm3; p  <  0.001); Table II 
summarizes differences in laboratory findings. 
There was also a  significant difference in use 
of β-blockers (90% vs. 17%; p < 0.001). That was 
the  only considerable difference in concomitant 
treatment. 
Percutaneous intervention
Patients in pairs had the  same vessel revas-
cularized. In the  HTX group patients received 
more frequently drug-eluting stent (DES) than in 
the control group (97% vs. 79%; p = 0.026). Mul-
tivessel revascularization was also more frequent 
in HTX patients (19% vs. 6%; p = 0.096). In 2 cases 
of revascularization in patients after HTX a biore-
sorbable scaffold was used. Otherwise angioplas-
ty techniques did not differ significantly between 
patients regarding use of   drug-eluting balloon 
(DEB), rotablation, cutting balloon, additional 
stents or balloons, or post-dilatation technique. 
There were no true bifurcations treated in either 
group. Dual antiplatelet therapy was applied ac-
cording to guidelines and there was no difference 
in use of clopidogrel or aspirin between groups.
Patients after heart transplant were treated ac-
cording to algorithms used in our center. Most pa-
tients were treated with cyclosporine, everolimus, 
tacrolimus, mycophenolate mofetil and steroids, 
which did not differ from the general HTX popu-
lation of our center. Frequencies of the use of par-
ticular medications are presented in Table III. 
Between patients with chronic kidney disease 
performed with SPSS ver. 23 (IBM, US) and R-Studio 
(RStudio 2016).
The propensity score matching method was 
planned to be used for the control group assign-
ment. However, due to the low number of patients 
and low calculated propensity scores, and planned 
further regression analysis, the manual matching 
of controls was performed [13, 14]. 
The forest plot was prepared with R statis-
tical software  [15]. For hazard ratio estimation 
of nonparametric parameters we plotted the haz-




Mean age of  patients in the  HTX group was 
54.6 ±11.4 compared to 58.8 ±10.8 (p  =  NS) in 
the control group. Most of the patients were male. 
Median time from heart transplant to PCI was 
13 years (4.4–22 years). Predominantly PCI was 
performed in the  left anterior descending artery 
(42% cases), then in the  right coronary artery 
(27%) and the left circumflex artery (15%). Match-
ing the  target vessels for revascularization be-
tween groups was 100%. 
The two groups did not differ significantly re-
garding risk factors, apart from dyslipidemia, 
which was more frequent in the  control group 
(91% vs. 48%; p  <  0.001), and chronic kidney 
disease, which was present in over 60% of  pa-
tients after heart transplantation (70% vs. 6%; 
p < 0.001). Details of comorbidity differences are 
tablepresented in Table I. The  EF in both groups 
differed significantly (57% vs. 44%; p = 0.02) but 
none of the patients in the HTX group had EF below 
40%. In laboratory findings, the  main differenc-
Table I. Characteristics and comorbidities in heart transplantation patients and control group
Parameter Post HTX (n = 33) Control (n = 33) P (χ2)
Female : male, n : n 7 : 26 8 : 27 NS
Age, mean (SD) [years] 54.6 (11.4) 58.8 (10.8) NS*
Time to HTX, median [years] 13.0 NA NA
Arterial hypertension, n (%) 24 (73) 28 (85) NS
Dyslipidemia, n (%) 16 (48) 30 (91) < 0.001
Diabetes type 2, n (%) 11 (33) 4 (12) NS
Chronic kidney disease, n (%) 23 (70) 2 (6) < 0.001
Obesity, n (%) 2 (6) 7 (21) NS
Prior ACS, n (%) 13 (39) 10 (30) NS
EF (%) 57 44 0.02*
HTX – heart transplantation, ACS – acute coronary syndrome, NA – not applicable, EF – ejection fraction. *t-test.
B. Guzik, E. Szczepanek, Ł. Niewiara, M. Nosal, K. Wierzbicki, M. Krzanowski, P. Szolc, B. Kapelak, K.F. Żmudka
792 Arch Med Sci 4, June / 2020
(CKD) and without there was no significant dif-
ferences in immunosuppressive treatment. Also, 
complexity of immunosuppressive treatment (use 
of 3 or more medications) did not differ between 
these groups. 
Long-term follow-up
Total time at risk was 127 859 person-days. 
Median follow-up time was 1325 days (3.63 
Table II. Laboratory findings in heart transplantation patients and control group
Parameter Post HTX Control P-value*
Total cholesterol, mean (SD) [mmol/l] 4.6 (0.2) 4.8 (0.2) NS
LDL, mean (SD) [mmol/l] 2.7 (0.2) 3.1 (0.2) NS
HDL, mean (SD) [mmol/l] 1.2 (0.1) 1.3 (0.1) NS
TG, mean (SD) [mmol/l] 1.3 (0.2) 1.4 (0.1) NS
Fasting glucose, mean (SD) [mmol/l] 6.2 (0.3) 6.4 (0.4) NS
Creatinine, mean (SD) [µmol/l] 204.0 (32.1) 104.7 (12.2) 0.006
eGFR, mean (SD) [ml/min/1.73 m2] 46.4 (4.6) 68.4 (5.9) 0.006
WBC, mean (SD) [103/µl] 7.9 (0.7) 8.1 (0.5) NS
Hb, mean (SD) [g/dl] 12.6 (0.4) 14.0 (0.3) 0.01
HCT, mean (SD) (%) 39.3 (1.0) 41.4 (0.8) NS
PLT, mean (SD) [103/µl] 187.4 (8.2) 240.8 (10.8) < 0.001
HTX – heart transplantation. *t-test. 
Table III. Concomitant medications used by heart transplantation patients
Immunosuppressive therapy Percentage of patients after HTX Chronic kidney disease 
P-value*
No Yes
Ciclosporin (%) 61 61 60 0.93
Everolimus (%) 44 38 50 0.51
Mycophenolate mofetil (%) 46 61 38 0.18
Steroids (%) 59 61 57 0.80
Tacrolimus (%) 27 23 29 0.72
HTX – heart transplantation. *P-value – χ2 test. 
Table IV. Endpoint comparison between groups
Parameter Post HTX Control P-value*
All-cause mortality, n (%) 16 (48) 2 (6) 0.001
MACCE, n (%) 26 (79) 11 (33) 0.014
ACS, n (%) 4 (12) 4 (12) 0.745
TVR, n (%) 7 (21) 7 (21) 0.651
Severe bleeding, n (%) 9 (27) 1 (3) 0.018
Hospitalization, n (%) 15 (45) 14 (42) 0.609
HTX – heart transplantation, MACCE – composite endpoint, ACS – acute coronary syndrome, TVR – total vessel revascularization. *P-value – χ2 test.
years; 255–4113 days). The  composite endpoint 
occurred in 49% of  patients. All-cause mortal-
ity occurred in 18 patients (24%); the  majority 
of deaths occurred in men. Table IV summarizes 
the comparison of endpoints between groups. 
There was a  significant difference in severe 
bleeding between groups. We looked into this group 
of patients with severe bleeding. None of the risk 
factors differed significantly apart from gender and 
age. Females had severe bleeding more frequently 
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that the only difference between patients in pairs 
would be HTX. In the literature, there is no com-
parison like this published. 
In this study, we analyzed patients several years 
after the heart transplant when coronary vasculop-
athy developed causing significant narrowing re-
quiring revascularization. In those patients, PCI pro-
longs life-span, as presented by Agarwal et al. [4].
In contemporary science, the propensity score 
matching method for control group assignment 
is gaining popularity, mainly due to its ability 
to decrease selection bias in case-control stud-
ies, similar to those observed in randomized 
control trials  [14]. However, precise calculation 
of  propensity scores and their relevant applica-
tion are crucial for internal and external validity 
of the study [17]. In our population obtained pro-
pensity scores were low, probably due to the small 
number of patients. Therefore, manual matching 
of  controls by age, sex, comorbidities and treat-
ed vessel was performed. Manual matching was 
very difficult due to common chronic kidney dis-
ease occurrence in the HTX group, which was hard 
Figure 1. Overall survival in heart transplantation 
and control group (KM estimates, log-rank test) 
Figure 2. Risk factors of death in Cox regression model
than men (9% vs. 28%; p = 0.042). Those patients 
had a higher mortality rate than patients without 
bleeding. Exploratory logistic regression for severe 
bleeding as an endpoint did not show any factors 
that could predict severe bleeding occurrence.
The search for prognostic factors
Patients after heart transplantation had worse 
survival compared to controls, as presented in Fig-
ure 1 (p  =  0.04 for Kaplan-Meier; log-rank test). 
When adjusted for age, gender, hypertension, dys-
lipidemia, diabetes and chronic kidney disease in 
the multivariable Cox-PH regression model, there 
was no significant difference in survival between 
cardiac transplant recipients and the control group. 
Chronic renal disease was a significant predictor 
of all-cause mortality (HR = 29.9; 95% CI: 2.3–393) 
as well as a protective effect of treatment of dys-
lipidemia (HR  =  0.07; 95% CI: 0.01–0.44). Heart 
transplantation itself did not increase risk of mor-
tality in this specific group (HR  =  1.06; 95% CI: 
0.1–11.2). Figure 2 shows a forest plot presenting 
the results of Cox-PH regression. In addition, we 
calculated the  continuous influence of  eGFR on 
survival. Figure 3 shows eGFR hazard ratio (log) 
changes with confidence intervals depending on 
its values. The  biggest fluctuations in slope can 
be observed between 50 ml/min and 80 ml/min. 
Discussion
The biggest study to date on long-term mor-
tality of  patients after heart transplant enrolled 
90 patients after PCI  [4]. In this study the  au-
thors compared patients after HTX and PCI to 
patients only after HTX. Coronary angioplasty did 
prolong life-span in those patients, compared to 
those with GV but not treated with PCI. In our 
study, we chose to compare 66 patients after PCI: 
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to find in the  control patient population. This 
could also be the additional reason for poor pro-
pensity matching. Arteriosclerosis plays a  min-
imal role in developing stenosis. That is why 
we found dyslipidemia more often in the  con-
trol group. There was a  huge difference in use 
of  β-blockers between groups. Patients after 
HTX have β-blockers introduced in our center 
when EF drops below 40% (none of the patients 
had decreased EF) or no bradyarrhythmia occurs 
in 24 h ECG monitoring.
Chronic kidney disease very often occurs in 
our patients requiring PCI as well as in those 
with chronic heart failure  [18]. Atherosclerosis 
and vascular calcifications are the most common 
causes of  increased mortality and morbidity in 
patients with CKD. Further analysis showed CKD 
to be a strong, independent predictor of mortali-
ty. Increased creatinine level is a known predictor 
of poor prognosis after decompensation of chron-
ic heart failure  [19]. Frequency of CKD after HTX 
is also caused by long use of immunosuppressive 
treatment, mainly calcineurin inhibitors (tacrolim-
us or cyclosporine). Patients after HTX have to use 
strong immunosuppressive treatment for lifetime, 
which causes several complications such as de-
velopment of CKD. Patients developing CKD were 
shifted to treatment with everolimus. 
In the  studied group DES stents were used 
more frequently (compared to the control group). 
The  literature suggests that DES stents do not 
bring an additional benefit in HTX patients [20].
When we looked at endpoints, there was a dis-
tinct difference in MACCE and all-cause mortality 
between groups. There was no difference in ACS 
and total vessel revascularization (TVR) between 
groups, which was expected to be a proof of un-
successful revascularization. Also, no difference 
in hospitalization frequencies between groups 
suggests good out-patient care, especially in HTX 
patients. In the exploratory regression model, we 
did not find any predictive factors of severe bleed-
ing. The reason for that could be sample size, as 
well as the fact that this was not the primary fo-
cus of  this study but an  accidental finding. This 
difference needs further exploration. 
While searching for predictive factors of a sig-
nificant difference of survival in the KM log-rank 
test it was surprising to find that undergoing 
heart transplant was not a predictive factor. Cox-
PH showed only CKD and dyslipidemia to play role 
in prediction of  death. Propensity score calcula-
tions confirmed our findings. Statin use had a pro-
tective influence on survival, as shown previously 
in the literature [4, 20]. 
Wellnhofer et al. in their paper presented sim-
ilar results to ours regarding survival but without 
a  control group. Stenting did not improve graft 
survival  [21]. They suggest that treatment with 
mycophenolate mofetil, and with concomitant 
treatment with statins, can have a beneficial ef-
fect on graft survival. In our population statins 
showed a  protective effect, but introduction 
of  mycophenolate mofetil into the  Cox-PH mod-
el only increased the predictive value of CKD (up 
to HR = 117.5; 95% CI: 3.6–3779). Use of myco-
phenolate mofetil was not significantly higher in 
patients with CKD. We did not adjust the model 
to the  revascularized vessel since it was a  cru-
cial factor in patient matching. We also observed 
a  protective effect of  statin use in our patients. 
This was consistent with studies presented in the 
literature. 
Since CKD was such a strong predictor of sur-
vival, we decided to look into whether HR changes 
depending on different values of  eGFR. Figure 3 
shows a plot of how HR (log) changes depending 
on the increase of eGFR. As expected, the higher 
the filtration rate, the less influence it has on sur-
vival. Of course, the confidence intervals are wide, 
but it is due to the small number of observations. 
But the  significance of  the  CKD influence is so 
strong that it is unlikely to be an error. 
Analyzing our data, we need to take the small 
sample size into consideration, especially when 
exploring subgroups of  patients. These findings 
need some further analysis since, to our best 
knowledge, there are no papers on this subject. 
CKD is one of the most frequent complications af-
ter heart transplant and a  recognized risk factor 
of graft failure [12, 22, 23].
There are two main limitations of  this study. 
The first is the small sample size. In different statis-
tics, we observed only trends instead of significant 
relationships, and the  confidence intervals were 
very wide. Increasing the number of patients with 
PCI after HTX would probably solve the problem. 
The second is heterogeneity of the study popu-
lation. Almost every patient after HTX was unique, 
due to different duration and course of heart fail-
ure preceding HTX as well as comorbidity.
Figure 3. Hazard ratio (log) depending on estimat-
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In conclusion, patients after HTX compared to 
controls had a  worse clinical outcome after PCI. 
When adjusted for comorbidities in the  Cox re-
gression model, there was no significant differ-
ence in survival between cardiac transplant re-
cipients and the control group. The difference in 
survival was caused by the  presence of  chronic 
kidney disease or diabetes, but not by the history 
of HTX. HTX patients more often suffered from se-
vere bleeding compared to controls. A protective 
effect of statin use was observed. Further research 
in this specific population is needed to improve 
patient outcomes. There was no significant differ-
ence in myocardial infarction rate, revasculariza-
tion or hospitalization rates.
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